Market Overview

Bristol-Myers Squibb, AbbVie Announce Progression-Free Survival Data from Phase 2 Multiple Myeloma Study

Related BMY
Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls
Bristol-Myers Squibb Posts Upbeat Q2 Results, Lifts Profit Forecast
Sanofi & Regeneron Enter Immuno-Oncology Collaboration - Analyst Blog (Zacks)

Squibb Company (NYSE: BMY) and AbbVie (NYSE: ABBV) today announced updated efficacy and safety data from a small,
randomized Phase 2, open-label study in patients with previously-treated
multiple myeloma that evaluated two doses of the investigational
monoclonal antibody elotuzumab (10 mg/kg and 20 mg/kg) in combination
with lenalidomide and low-dose dexamethasone. In the 10 mg/kg arm
(N=36), which is the dose used in the ongoing Phase 3 trials, median
progression-free survival (PFS), or the time without disease
progression, was 33 months after a median follow-up of 20.8 months (95%
CI: 14.9-NA) and the objective response rate (ORR) was 92%. As
previously reported, median PFS was 18 months in the 20 mg/kg arm (N=37)
after a median follow-up

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (ABBV)

Get Benzinga's Newsletters